Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuronâs technology platform is capable of developing and producing an orally stable therapeutic as a potential âoral targeted therapyâ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.
Immuron has one marketed product, which provides proof of concept for its Oral Immune Technology Platform, and a pipeline of products at various stages of clinical and earlier development. Immuronâs marketed product, TravelanÂŽ, is for the prevention of travellersâ diarrhoea. TravelanÂŽ is a non-absorbable, safe product which is composed of anti-bacterial antibodies that work on the gut immune system and gut microbiome. TravelanÂŽ has been proven in clinical studies to offer over 90% protection against travellers' diarrhoea and is therefore a major new breakthrough when travelling to high risk destinations. The product is licensed in Australia and sold as a dietary supplement in the USA.
Source
